CAU
ADMA icon

Caxton Associates (UK)’s ADMA Biologics ADMA Stock Holding History

Caxton Associates (UK)’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$334K Buy
39,928
+24,820
+164% +$226K 0.01% 622
2026
Q1 		$136K Buy
+15,108
New +$238K ﹤0.01% 736
2025
Q3 		– Sell
-33,664
Closed -$613K – 679
2025
Q2 		$613K Hold
33,664
– – 0.02% 379
2025
Q1 		$668K Buy
+33,664
New +$582K 0.02% 413

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Caxton Associates (UK)'s ADMA Position: Q2 2026 in Review

Caxton Associates (UK) increased its ADMA Biologics (ADMA) stake by 164% in Q2 2026, buying an estimated $226K and bringing the position to 39,928 shares worth $334K. The position accounts for 0.01% of the portfolio, ranked #622.

Caxton Associates (UK) first reported a position in ADMA in Q1 2025 and has held it in 4 quarters since. The position peaked at $668K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Caxton Associates (UK) held 39,928 shares of ADMA Biologics worth $334K as of Q2 2026.
  • Caxton Associates (UK) bought 24,820 ADMA Biologics shares in Q2 2026, an estimated $226K.
  • ADMA Biologics made up 0.01% of Caxton Associates (UK)'s portfolio in Q2 2026, its #622 holding.
  • Caxton Associates (UK) first reported a position in ADMA Biologics in Q1 2025 and has held it in 4 quarters since.
  • Caxton Associates (UK)'s ADMA Biologics position peaked at $668K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.